logo
Sign In
Farxiga vs. GlyxambiBerinert vs. CinryzeEmgality vs. QuliptaFarxiga vs. InvokanaFirazyr vs. SajazirGlyxambi vs. InvokanaInvokamet vs. SynjardyOpzelura vs. DupixentOrencia vs. RinvoqQulipta vs. VyeptiStelara vs. TremfyaSynjardy vs. VictozaTaltz vs. BimzelxVyepti vs. Nurtec ODTView all Comparisons
ADHD drugsAnxiety drugsAsthma drugsAtopic dermatitis drugsDepression drugsHeart failure drugsHypertension drugsLymphoma drugsOsteoarthritis drugsRheumatoid arthritis drugsRosacea drugsSchizophrenia drugsType 2 Diabetes drugsView all Indications
Bayer drugsAbbVie drugsAstraZeneca drugsEli Lilly and Company drugsGenetech drugsGlaxoSmithKline (GSK) drugsNovartis drugsPfizer drugsTakeda Pharmaceuticals drugsTeva Pharmaceuticals drugsAmgen drugsView all Manufacturers
Beta-Adrenergic BlockerAngiotensin Converting Enzyme InhibitorAngiotensin 2 Receptor BlockerCalcium Channel BlockerDiureticsHMG-CoA Reductase InhibitorProton Pump InhibitorSelective Serotonin Reuptake InhibitorNorepinephrine Reuptake InhibitorBenzodiazepinesOpioid AgonistsNonsteroidal Anti-inflammatory DrugsAntiepileptic AgentsAntipsychoticsAntihistaminesView all Classes
Wegovy®Ozempic®Mounjaro®Zepbound®Jardiance®Farxiga®Dupixent®Trulicity®Lyrica®Lipitor®Effexor®Concerta®Depakote®Trintellix®Rexulti®Rinvoq®Verzenio®Taltz®
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
PrescriberPoint
HIPAA Logo
HIPAA COMPLIANT
SOC 2 Logo
Soc 2 Type II
For ProvidersRequest DemoJoin Research Panel
Prescribing toolsPrescribing InfoCoverageSavingsPatient ResourcesA-Z IndicationsCompare Drugs
CompanyPartnershipsAboutCareersContact Us
Get the latest insights in your inbox
  • Terms and Conditions
  • Privacy Policy
  • © 2026 PrescriberPoint. All Rights Reserved.
    1. Home
    2. Manufacturers
    3. Sumitomo Pharma America, Inc.

    Sumitomo Pharma America, Inc. drugs

    FiltersReset Filters
    4 results

    • aptiom

      (ESLICARBAZEPINE ACETATE)
      Sumitomo Pharma America, Inc.
      Usage: APTIOM is used to treat partial-onset seizures in patients aged 4 years and older.

    • gemtesa

      (vibegron)
      Sumitomo Pharma America, Inc.
      Usage: GEMTESA® is indicated for the treatment of overactive bladder (OAB) in adults, characterized by urge urinary incontinence, urgency, and urinary frequency. It is also indicated for adult males with OAB symptoms who are undergoing pharmacological therapy for benign prostatic hyperplasia (BPH).

    • latuda

      (lurasidone hydrochloride)
      Sumitomo Pharma America, Inc.
      Usage: LATUDA is indicated for the treatment of schizophrenia in patients aged 13-17, monotherapy for bipolar depression in those aged 10-17, and as adjunctive treatment with lithium or valproate for adult patients with bipolar depression.

    • rethymic

      (allogenic thymocyte-depleted thymus tissue-agdc)
      Sumitomo Pharma America, Inc.
      Usage: RETHYMIC® is indicated for immune reconstitution in pediatric patients with congenital athymia. It is not indicated for the treatment of severe combined immunodeficiency (SCID).